dyslipidemia
DYSLIPIDEMIA
Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.

Definition

  • An abnormality in lipoprotein metabolism that results in elevations of low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, and/or non-high-density lipoprotein cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein cholesterol (HDL-C) levels
  • Increase in serum concentration of total cholesterol, LDL, triglycerides or non-HDL-C is equivalent to increased risk for cardiovascular diseases

Etiology

  • Depends on the type of dyslipidemia
  • Hereditary disorders associated with dyslipidemia include familial hypercholesterolemia, familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
  • Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, obstructive liver disease, Cushing’s syndrome, metabolic syndrome, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Mar 2016
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
13 Aug 2016
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
01 Mar 2016
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
16 Dec 2018
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.